However, its application to solid tumors remains constrained by antigen heterogeneity and on-target, off-tumor toxicities. One critical emerging approach to combat this challenge is logic-gated ...

Tumor heterogeneity and tumor mutational burden (TMB) are novel biomarkers associated with the response to immunotherapy in non-small cell lung cancer (NSCLC), but studies report conflicting results.

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Negative Breast Cancer Market Insight, Epidemiology and Market Forecast - 2035" report delivers comprehensive insights into triple-negative breast cancer, i ...

primary focus on cancer vaccines. The shot is the lead product candidate from BioNTech's FixVac platform and is based on a combination of four mRNA-encoded, melanoma-associated antigens – NY-ESO ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Given that only a small fraction of patients with cancer exhibits specific markers making them eligible for effective ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The ...

Although immunotherapies and biomarker-driven interventions have transformed lung cancer outcomes, Martin Edelman, MD, Fox Chase Cancer Center, highlighted the present challenge hindering ...